Formulations comprising an inhibitor of carboxypeptidase U...

Details Formulations comprising an inhibitor of carboxypeptidase U... Formulations comprising an inhibitor of carboxypeptidase U...

2005-12-13

2005-12-13

Lukton, David (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C530S331000, C562S557000

Reexamination Certificate

active

06974800

ABSTRACT:
The present invention relates to pharmaceutical formulations of an inhibitor of carboxypeptidase U (CPU) and a thrombin inhibitor in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, as well as a kit of parts, a method for treatment and use of the formulations for the treatment of a condition in which inhibition of CPU and/or inhibition of thrombin are required or desired.

REFERENCES:
patent: 3091569 (1963-05-01), Sheffner
patent: 3766206 (1973-10-01), Hess et al.
patent: 4113715 (1978-09-01), Ondetti et al.
patent: 4177277 (1979-12-01), Ondetti et al.
patent: 5254579 (1993-10-01), Poli et al.
patent: 5955433 (1999-09-01), Bylund et al.
patent: 5993815 (1999-11-01), Bajzar et al.
patent: 6020510 (2000-02-01), Franson et al.
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6326386 (2001-12-01), Watson et al.
patent: 6410587 (2002-06-01), Grainger et al.
patent: 3838467 (1990-05-01), None
patent: 0300100 (1989-01-01), None
patent: 1393338 (1965-02-01), None
patent: 2266502 (1975-10-01), None
patent: 2430945 (1980-02-01), None
patent: 1593469 (1981-07-01), None
patent: 94/29336 (1994-12-01), None
patent: 9616671 (1996-06-01), None
patent: WO 97/49673 (1997-12-01), None
Bajzar, J Biol Chem 271 16603, 1996.
Boffa, J Biol Chem 273 2127, 1998.
Ondetti, Biochem 18, 1427, 1979.
Current Opinion in Cardiology, vol. 12, 1997, Jonathan Alexander, MD, “Adjunctive therapy for acute myocardial infarction” p. 453-458.
U.S. Appl. No. 09/600,660 of Linschoten, et al., filed Jul. 20, 2000.
U.S. Appl. No. 09/600,661 of Linschoten, et al., filed Jul. 20, 2000.
Skidgel, R. A., “Structure and function of mamalian zinc carboxypeptidases” inZinc Metalloproteases in Health and DiseaseN.M. Hooper, Ed., Taylor & Francis, London, pp. 241-283 (1996).
Bouma, et al, “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U),” Thrombosis Res. 101, 329-354 (2001).
Zhu et al, “Isolation and characterization of americanin, a specific inhibitor of thrombin, from the salivary glands of the lone star tickAmblyomma americanum(L.),” Exp. Parasitol. 87, 30-38 (1997) (abstract only).
Bajzar et al., “Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor,” J Biol Chem., 270, 14477-84 (1995) (abstract only).

Affiliated with

Also associated with

Rating

Formulations comprising an inhibitor of carboxypeptidase U... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations comprising an inhibitor of carboxypeptidase U..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations comprising an inhibitor of carboxypeptidase U... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3515253